Protease stable cell wall lysing enzymes

a stable, cell wall technology, applied in the direction of instruments, antibacterial agents, peptide/protein ingredients, etc., can solve the problems of only being used in limited quantities by protease inhibitors for stabilizing and affecting the stability of the etc., to achieve the effect of stable cell wall lysing enzymes

Inactive Publication Date: 2013-11-07
HYGLOS INVEST GMBH
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]Thus the object of the present invention

Problems solved by technology

Pathogenic bacteria appear at many places and cause enormous health problems by infections as well as high economic costs, e.g. also by unwanted bacteria contamination in the food, cosmetic and environmental industry.
In health care the problems are increasing more and more due to germs resistant to antibiotics, so that it is searched hand-wringing for alternatives to antibiotics.
However protease inhibitors could be only limited used for stabilizing of cel

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protease stable cell wall lysing enzymes
  • Protease stable cell wall lysing enzymes
  • Protease stable cell wall lysing enzymes

Examples

Experimental program
Comparison scheme
Effect test

example 1

Protease Digest of PlyPitti26

[0069]It was performed a digest of PlyPitti26 with the proteases thrombin and V8. Each 90 μl protein solution (protein concentration 1.35 mg / ml) were tampered with 10 μl thrombin and in control samples only tempered with plasmin. For the V8 protease digest 99 μl protein solution and 1 protease solution were used. The concentration of the protease stock solutions was each 500 μg / ml. The samples were incubated in a 20 mM Tris / HCl pH 7.5, 10 mM DTE, 0.1 mM ZnSO4 Buffer over night at 25° C. A part of the samples was tempered with SDS gel-application buffer and was analysed on SDS polyacrylamide gels after boiling.

[0070]It was found that PlyPitti26 is degraded completely by thrombin, wherein two relative large protein fragments emerged, of which the one contained the CHAP-domain and the other the amidase domain and the CBD. In a digest with V8 protease several smaller, but also defined protein fragments emerged. In a control digest with plasmin no fragmentati...

example 2

Activity Test of Untreated PlyPitti26 and PlyPitti26 Treated with Proteases

[0071]In further experiments the samples were tested in the liquid lysis test on the lysis activity towards Staphylococcus cells. The liquid lysis test is an activity test for cell wall lysing enzymes, in which the bacterial cell lysis was measured in real time via light scattering in the photometer. The absorption at a wave length of 600 nm is thereby a measure for the number of existing bacteria cells. If the bacteria lyse the sample solution is getting clear by degrees and the measured absorption decreases in the ideal case down to a value of zero. Staphylococcus bacteria were cultivated in BHI medium to an OD600 of about 0.8. The not heat activated cells were harvested and resuspended to an OD600 of about 1 in TBST buffer (20 mM Tris / HCl pH 7.5, 60 mM NaCl, 0.1% Tween, 2 mM CaCl2). 990 μl cell suspension was tempered each with 10 μl enzyme solution (enzyme concentration in the test 10 μg / ml) and the decre...

example 3

Stabilization of CHAP-AmiPitti26-CBDUSA

[0073]A synthetically produced endolysin variant active against staphylococci, which consists of the enzymatically active domains CHAP and Ami of the endolysins of PlyPitti26 and of the cell wall binding domain (CBD) of the endolysin of the prophage Φ SA2USA deriving from the genome of the MRSA strain USA300 (Diep et al., The Lancet, 2006, 367, 731-739; database accession number NC—007793) is described as CHAP-AmiPitti26-CBDUSA.

[0074]To stabilize this protein against thrombin digest and digest by V8 protease, both the thrombin cleavage site and V8 cleavage sites lying in the linker between the CHAP- and amidase domains were modified by amino acid substitutions by means of site-directed mutagenesis. The single, double, triple and quadruple mutations performed for that purpose are summarized in table 3. For all mutations given in table 3, endolysin activity against staphylococci was still detected in the plate lysis test, as described below after...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Biological propertiesaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, staphylococcus peptidase I (V8 Protease), plasmin, streptopain, bacillolysin and/or thrombin cleavage site. The invention further relates to nucleic acids with a sequence encoding a polypeptide according to the present invention.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. application Ser. No. 12 / 674,369, filed as a national phase application under 35 U.S.C. §371 of International Patent Application No. PCT / DE2008 / 001378, filed Aug. 19, 2008, which claims priority to European Patent Application No. EP 07 114 785.4, filed Aug. 22, 2007, U.S. Provisional Patent Application No. 60 / 957,351 filed Aug. 22, 2007, German Patent Application No. DE 10 2007 061 929.6, filed Dec. 21, 2007, U.S. Provisional Patent Application No. 61 / 032,211 filed Feb. 28, 2008, European Patent Application No. EP 08 152 096.7, filed Feb. 28, 2008 and German Patent Application No. DE 10 2008 023 448.6, filed May 14, 2008. The entire text of each of the above-referenced disclosures is specifically incorporated herein by reference without disclaimer.BACKGROUND OF THE INVENTION[0002]The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N9/00A01N63/50
CPCC12N9/00C12N9/503C12N9/80A61P31/04A01N63/50A01N63/20A01N63/40
Inventor GRALLERT, HOLGERFORCHHEIM, MICHAEL
Owner HYGLOS INVEST GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products